Endothelin-1 (ET-1) promotes MMP-2 and MMP-9 induction involving the transcription factor NF-κB in human osteosarcoma

被引:91
作者
Felx, Melanie
Guyot, Marie-Claude
Isler, Marc
Turcotte, Robert E.
Doyon, Jose
Khatib, Abdel-Majid
Leclerc, Severine
Moreau, Alain
Moldovan, Florina
机构
[1] CHU St Justine Hosp, Res Ctr, Montreal, PQ, Canada
[2] Univ Montreal, Hop Maison Neuve Rosemont, Montreal, PQ, Canada
[3] McGill Univ, Ctr Hlth, Montreal, PQ, Canada
[4] INSERM, Inst Mol Genet, U 716, Lab Pharmacol Expt & Clin, Paris, France
[5] Univ Montreal, Fac Dent, Montreal, PQ, Canada
关键词
endothelin-1 (ET-1); ETA; gelatinase; nuclear factor kappa B (NF-kappa B); matrix metalloproteinase (MMP); osteosarcoma;
D O I
10.1042/CS20050286
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
In the present study, we have investigated the effect of (i) ET-I (endothelin-1) and its precursor, big ET-1, on MMP (matrix metal loproteinase)-2 and MMP-9 synthesis and activity in osteosarcoma tissue, and (ii) ET-I receptor antagonists on cell invasion. Using Western blotting, zymography, RT-PCR (reverse transcription-PCR), immunohistochemistry, immunofluorescence and Northern blotting, we have shown that ET-I and ET-I receptors (ETA and ETB) were expressed in these cells. Additionally, we have demonstrated that ET-I markedly induced the synthesis and activity of MMP-2, which was significantly increased when compared with MMP-9. Furthermore, inhibition of NF-kappa B (nuclear factor kappa B) activation blocked MMP-2 production and activity, indicating the involvement of NF-kappa B, a ubiquitous transcription factor playing a central role in the differentiation, proliferation and malignant transformation. Since ET-I acts as an autocrine mediator through gelatinase induction and because inhibition of ETA receptor is beneficial for reducing both basal and ET-I-induced osteosarcoma cell invasion, targeting this receptor could be an attractive therapeutic alternative for the successful treatment of osteosarcoma.
引用
收藏
页码:645 / 654
页数:10
相关论文
共 29 条
[1]  
Ali H, 2000, J CARDIOVASC PHARM, V36, pS69
[2]   NFκB:: A pivotal transcription factor in prostate cancer metastasis to bone [J].
Andela, VB ;
Gordon, AH ;
Zotalis, G ;
Rosier, RN ;
Goater, JJ ;
Lewis, GD ;
Schwarz, EM ;
Puzas, JE ;
O'Keefe, RJ .
CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, 2003, (415) :S75-S85
[3]  
Bagnato A, 1999, CANCER RES, V59, P720
[4]  
Bagnato Anna, 2004, Cancer Treat Res, V119, P293
[5]   The matrix metalloproteinases and their synthetic inhibitors in tumor progression [J].
Chantrain, C ;
DeClerck, YA .
M S-MEDECINE SCIENCES, 2002, 18 (05) :565-575
[6]   New functions for the matrix metalloproteinases in cancer progression [J].
Egeblad, M ;
Werb, Z .
NATURE REVIEWS CANCER, 2002, 2 (03) :161-174
[7]   Effects of oncological surgery on endothelin-1 secretion in patients with operable gastric cancer [J].
Ferrari-Bravo, A ;
Franciosi, C ;
Lissoni, P ;
Fumagalli, L ;
Uggeri, F .
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2000, 15 (01) :56-57
[8]  
Gorlick R, 2003, CLIN CANCER RES, V9, P5442
[9]   Endothelin-1 binding to endothelin receptors in the rat anterior pituitary gland:: Possible formation of an ETA-ETB receptor heterodimer [J].
Harada, N ;
Himeno, A ;
Shigematsu, K ;
Sumikawa, K ;
Niwa, M .
CELLULAR AND MOLECULAR NEUROBIOLOGY, 2002, 22 (02) :207-226
[10]   RNA quantitation by fluorescence-based solution assay: RiboGreen reagent characterization [J].
Jones, LJ ;
Yue, ST ;
Cheung, CY ;
Singer, VL .
ANALYTICAL BIOCHEMISTRY, 1998, 265 (02) :368-374